Form 8-K - Current report:
SEC Accession No. 0001193125-25-066261
Filing Date
2025-03-28
Accepted
2025-03-28 07:36:42
Documents
14
Period of Report
2025-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d927069d8k.htm   iXBRL 8-K 28019
2 EX-99.1 d927069dex991.htm EX-99.1 41449
  Complete submission text file 0001193125-25-066261.txt   207449

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA snse-20250328.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE snse-20250328_lab.xml EX-101.LAB 19500
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE snse-20250328_pre.xml EX-101.PRE 12152
17 EXTRACTED XBRL INSTANCE DOCUMENT d927069d8k_htm.xml XML 3996
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39980 | Film No.: 25781503
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)